BioAtla Inc
Research BioAtla Inc (BCAB) on Bullrun: market cap USD 5.40M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBCAB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.40M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 50.62M
- Free cash flow-USD 37.18M
Valuation Snapshot
latest market cap is USD 5.40M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.00M | USD 59.60M | -USD 48.20M | n/a | -1.01 | USD 7.12M | USD 6.20M | -USD 36.19M |
| FY2024 | USD 11.00M | USD 69.80M | -USD 71.94M | n/a | -1.44 | USD 49.05M | USD 836.00K | USD 14.27M |
| FY2023 | USD 0 | USD 123.50M | n/a | n/a | -2.58 | USD 111.47M | USD 2.46M | USD 70.67M |
| FY2022 | n/a | -USD 106.48M | n/a | n/a | -2.74 | USD 215.51M | USD 3.98M | USD 180.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.40M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 36.05M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 34.34M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 117.92M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 880.36M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.17B | n/a | n/a | n/a |
About BioAtla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioAtla Inc's market cap?
BioAtla Inc's market capitalization is USD 5.40M.
What does BioAtla Inc do?
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma.